News from boehringer ingelheim A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 08, 2014, 13:30 ET

New Data Show Idarucizumab* Reverses Anticoagulant Effects of Dabigatran (PRADAXA®) in Middle-Aged, Elderly and Renally Impaired Volunteers

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced phase I data that showed administration of investigational idarucizumab in healthy...

Nov 18, 2014, 10:00 ET

New Data Show Idarucizumab* Restores Wound-Site Formation of Fibrin, a Key Component of Blood Clotting, in Healthy Volunteers Given Pradaxa® (dabigatran etexilate mesylate)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced phase I study sub-analyses showing that its investigational antidote idarucizumab...

Nov 18, 2014, 10:00 ET

Interim Data Reinforce Safety and Effectiveness of Pradaxa® (dabigatran etexilate mesylate) versus Warfarin in Routine Care of Patients with Non-valvular Atrial Fibrillation

Brigham and Women's Hospital and Boehringer Ingelheim Pharmaceuticals, Inc. today announced interim findings from an analysis of two health...

Nov 17, 2014, 16:00 ET
Eli Lilly and Company logo.

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

Empagliflozin tablets reduced hemoglobin A1C (a measure of average blood sugar over the past two to three months), body weight and several markers...

Nov 17, 2014, 10:00 ET

U.S. Department of Defense Study Supports Favorable Benefit-Risk Profile of Pradaxa® (dabigatran etexilate mesylate) for Reducing Stroke Risk in Non-valvular Atrial Fibrillation

Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a U.S. Department of Defense cohort analysis of the Military Health System...

Nov 17, 2014, 08:00 ET

New Survey Uncovers Critical Need to Break Down Barriers and Improve Communication and Education about the Link between Atrial Fibrillation and Devastating Impact of Stroke

Released today, a new survey of more than 1,200 physicians, patients with atrial fibrillation (AFib) and their caregivers uncovered important...

Nov 10, 2014, 08:00 ET

New Real-World Safety and Efficacy Data on Pradaxa® (dabigatran etexilate mesylate) to be Presented at American Heart Association Scientific Sessions

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that two separate comparative analyses evaluating the safety and efficacy of...

Nov 10, 2014, 08:00 ET

Boehringer Ingelheim Initiates U.S. Sites in First-Ever Global Phase III Trial of Investigational Antidote in Patients Taking PRADAXA® (dabigatran etexilate mesylate)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced the initiation of U.S. sites of the RE-VERSE AD™ trial (NCT02104947), a phase...

Nov 03, 2014, 10:00 ET

Boehringer Ingelheim Announces U.S. Filing Acceptance of New Drug Application for Spiriva® Respimat® (tiotropium bromide) Inhalation Spray for the Treatment of Asthma

 Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for...

Nov 03, 2014, 08:00 ET

FDA Study of Medicare Patients Reaffirms Safety and Efficacy Profile of Pradaxa® (dabigatran etexilate mesylate) for NVAF

 A U.S. Food and Drug Administration (FDA) study of more than 134,000 Medicare patients found that Pradaxa® (dabigatran etexilate...

Oct 27, 2014, 09:45 ET

Boehringer Ingelheim Presents Data for the Co-Administration of Two Approved Products for COPD Patients

 Boehringer Ingelheim today presented data from the ANHELTO™ 1&2 studies (NCT01694771/NCT01696058) that evaluated the...

Oct 21, 2014, 08:30 ET
Eli Lilly and Company logo.

U.S. Food and Drug Administration accepts filing of new drug application for empagliflozin/metformin fixed-dose combination

The U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for empagliflozin plus immediate-release...

Oct 21, 2014, 08:00 ET

Boehringer Ingelheim initiates global Phase III study investigating nintedanib in patients with colorectal cancer

 Boehringer Ingelheim today announced enrollment of the first patient in a new global Phase III study in patients with metastatic colorectal...

Oct 20, 2014, 15:00 ET

OFEV® (nintedanib) Now Available in the United States

 Boehringer Ingelheim Pharmaceuticals, Inc. has announced that OFEV® (nintedanib) capsules are now commercially available in the United...

Oct 15, 2014, 18:55 ET

FDA Approves Boehringer Ingelheim's OFEV® (nintedanib) as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved OFEV® (nintedanib)...

Oct 08, 2014, 08:00 ET

New COPD Maintenance Treatment Striverdi® Respimat® (olodaterol) Inhalation Spray Now Available in U.S. Pharmacies

 Boehringer Ingelheim today announced that Striverdi® Respimat® (olodaterol) Inhalation Spray 5 mcg is now available by prescription...

Sep 29, 2014, 08:00 ET

Head-to-head Phase III trial demonstrates superior progression-free survival of afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung

Phase III data from Boehringer Ingelheim's LUX-Lung 8 trial, the first study to evaluate the superiority of afatinib versus erlotinib in patients...

Sep 26, 2014, 12:30 ET

Boehringer Ingelheim Statement on FDA Drug Development Public Meeting for Idiopathic Pulmonary Fibrosis (IPF)

RIDGEFIELD, Conn., Sept. 26, 2014 /PRNewswire/ - Boehringer Ingelheim applauds the U.S. Food and Drug Administration (FDA) for conducting...

Sep 25, 2014, 08:00 ET

Boehringer Ingelheim Announces FDA Approval of Spiriva® Respimat® (tiotropium bromide) Inhalation Spray for the Maintenance Treatment of COPD

 Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Spiriva®...

Sep 18, 2014, 06:00 ET

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

 Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, today jointly announce an exclusive...